The Medical Letter on Drugs and Therapeutics
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin (Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.1

ACUTE OTITIS EXTERNA – S. aureus or P. aeruginosa infection is the most common cause of acute otitis externa.2 In a meta-analysis of 19 trials, topical antibiotics, antiseptics, glucocorticoids, and acidifying agents were equally effective.3 Topical antibiotic therapy is the treatment of choice. Cure rates with topical ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
Article code: 1553c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian